|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM234371358 |
| 003 |
DE-627 |
| 005 |
20231224101129.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2014 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.11.010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0781.xml
|
| 035 |
|
|
|a (DE-627)NLM234371358
|
| 035 |
|
|
|a (NLM)24412909
|
| 035 |
|
|
|a (PII)S1521-6616(13)00312-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Darling, Alanna R
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum
|
| 264 |
|
1 |
|c 2014
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.04.2014
|
| 500 |
|
|
|a Date Revised 21.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Individuals with atopic dermatitis (AD) are susceptible to a severe, potentially fatal, systemic infection and inflammatory response following exposure to Vaccinia virus (VV). IL-10 acts both as an inducer of Th2 responses and as a regulator of T cell activation. It has been shown to limit skin inflammation elicited by contact sensitizers. AD exacerbations have been associated with decreased IL-10 function. We used IL-10(-/-) mice to test the role of the cytokine in VV immunity. They exhibited larger primary lesions and increased cutaneous neutrophil infiltration compared to wild-type (WT) counterparts. This was associated with enhanced production of IL-17A, IL-17F and CXCL2. Paradoxically, despite intact adaptive immune responses, tissue viral burdens were increased in IL-10(-/-) mice. These findings suggest that IL-10 is important in limiting skin inflammation induced by VV and that abnormal IL-17-driven neutrophil recruitment at the primary infection site in the skin results in increased systemic viral dissemination
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Atopic dermatitis
|
| 650 |
|
4 |
|a Eczema vaccinatum
|
| 650 |
|
4 |
|a Vaccine
|
| 650 |
|
7 |
|a Interleukin-17
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 700 |
1 |
|
|a Freyschmidt, Eva-Jasmin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Burton, Oliver T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koleoglou, Kyle J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oyoshi, Michiko K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oettgen, Hans C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 150(2014), 2 vom: 09. Feb., Seite 153-60
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:150
|g year:2014
|g number:2
|g day:09
|g month:02
|g pages:153-60
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.11.010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 150
|j 2014
|e 2
|b 09
|c 02
|h 153-60
|